NCT03897374 Strategic Targeting for Optimal Prevention of Cancer
| NCT ID | NCT03897374 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ClinLogic LLC |
| Condition | Early Detection of Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 120,000 participants |
| Start Date | 2025-03-26 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120,000 participants in total. It began in 2025-03-26 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary goal of the study is to record data over the observation period to evaluate the clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary genetic cancer risk profile and to help guide physicians to pursue preventative measures, which may lead to early detection and treatment of the condition.
Eligibility Criteria
Inclusion Criteria: * Study subjects may be included in the Clinical Trial if they meet all of the following inclusion criteria: * individuals, ages 65 years or older; * must have met medical necessity for hereditary cancer genomic testing and allowed the physician to test based on medical necessity; * hereditary cancer diagnostic test was ordered by a physician related to individual subject care considerations. * study subject has or had cancer * study subject has at least one family member with cirrent or past cancer Exclusion Criteria: * Study subjects will be excluded from the study if any of the following criteria apply: • study subject is currently hospitalized or incarcerated; * study subject is unable to provide an accurate history due to mental incapacity * study subject is currently abusing illicit and/or prescription drugs;
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03897374 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Early Detection of Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03897374 currently recruiting?
Yes, NCT03897374 is actively recruiting participants. Contact the research team at stopcancer@callmdglobal.com for enrollment information.
Where is the NCT03897374 trial being conducted?
This trial is being conducted at Prosper, United States.
Who is sponsoring the NCT03897374 clinical trial?
NCT03897374 is sponsored by ClinLogic LLC. The trial plans to enroll 120,000 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.